The European Medicines Agency has proposed revising its five-year old guideline on medicinal products containing genetically-modified cells to primarily address the availability of improved genome editing technologies and to incorporate quality, non-clinical and clinical issues specific to chimeric antigen receptor (CAR)-T cells.
The proposed changes are outlined in a concept paper in which the EMA notes that its existing guideline...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?